Prior research has demonstrated that in NSCLC, IL-34 secreted by tumor cells can modulate the activity of TAM through AKT signaling activation, hence augmenting local immunosuppression and facilitating the survival of chemotherapy-resistant tumor cells. The gene discussed is IL34; the disease is non-small cell lung carcinoma.